These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2412053)

  • 1. Effects of ketanserin on platelet function and red cell filterability in hypertension and peripheral vascular disease.
    Zannad F; Voisin P; Pointel JP; Schmitt C; Freitag B; Stoltz JF
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S32-4. PubMed ID: 2412053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ketanserin and red blood cell sodium content in hypertension.
    De Cree J; Leempoels J; Demoen B; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S41-3. PubMed ID: 2412056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S26-8. PubMed ID: 2412051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans.
    De Clerck F; Xhonneux B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S23-5. PubMed ID: 2412050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ketanserin (S2-receptor blocking agent), platelet activity and chronic alcoholism.
    Santini P; Ceccanti M; De Lorenzo A; Pisculli M; Di Giovanni MG; Cavaleri G; Attilia ML; Berbellini A
    Int J Clin Pharmacol Res; 1986; 6(1):73-6. PubMed ID: 2937746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon.
    Longstaff J; Gush R; Williams EH; Jayson MI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S99-101. PubMed ID: 2412071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
    De Clerck F; Xhonneux B
    Agents Actions; 1986 Mar; 17(5-6):515-26. PubMed ID: 2939698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
    de Clerck F; David JL; Janssen PA
    Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ketanserin prevents platelet aggregation and endotoxin-induced pulmonary vasoconstriction.
    Meuleman TR; Hill DC; Port JD; Stanley TH; Pace NL; Mohammad SF
    Crit Care Med; 1983 Aug; 11(8):606-11. PubMed ID: 6872549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet hypersensitivity to serotonin after prolonged ketanserin intake?
    Arnout J; Van Russelt M; Deckmyn H; Vermylen J; Fiocchi R; Lijnen P; Amery A
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S20-2. PubMed ID: 2412049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.
    Bevan J; Heptinstall S
    Thromb Res; 1983 Jun; 30(5):415-23. PubMed ID: 6612677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood pressure, 5-OH indoleacetic acid, and vanilmandelic acid excretion and blood platelet aggregation in hypertensive patients treated with ketanserin.
    Dzúrik R; Fetkovská N; Brimichová G; Tison P
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S29-31. PubMed ID: 2412052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolongation of rat tail bleeding time by ketanserin: mechanisms of action.
    Buczko W; Gambino MC; De Gaetano G
    Eur J Pharmacol; 1984 Aug; 103(3-4):261-8. PubMed ID: 6237923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive action and serotonin-induced platelet aggregation during long-term ketanserin treatment in hypertensive patients.
    Amery A; Fagard R; Fiocchi R; Lijnen P; Staessen J; Vermylen J
    J Cardiovasc Pharmacol; 1984; 6(1):182-5. PubMed ID: 6199602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of serotonin in patients with acute respiratory failure.
    Huval WV; Lelcuk S; Shepro D; Hechtman HB
    Ann Surg; 1984 Aug; 200(2):166-72. PubMed ID: 6547816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin-induced platelet aggregation predicts the antihypertensive response to serotonin receptor antagonists.
    Gleerup G; Persson B; Hedner T; Winther K
    Eur J Clin Pharmacol; 1993; 44(2):121-5. PubMed ID: 8453957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemorheological effects of ketanserin, a selective 5-HT2 receptor antagonist, in aged, spontaneously hypertensive dogs.
    De Clerck F; Jageneau A; Dom J
    Arch Int Pharmacodyn Ther; 1982 Jul; 258(1):100-15. PubMed ID: 7138138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of ketanserin, a 5-HT2-receptor antagonist, on 5-hydroxytryptamine-induced irreversible platelet aggregation in patients with cardiovascular diseases.
    De Cree J; Leempoels J; Demoen B; Roels V; Verhaegen H
    Agents Actions; 1985 Jul; 16(5):313-7. PubMed ID: 2931964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ketanserin on hemodynamics, plasma-catecholamine concentrations, and serotonin uptake by platelets in volunteers and patients with congestive heart failure.
    Grobecker H; Gessler I; Delius W; Dominiak P; Kees F
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S102-4. PubMed ID: 2412024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of MDL 28,133A, a 5-HT2 receptor antagonist, on platelet aggregation and coronary thrombosis in dogs.
    Hsieh CP; Sakai K; Bruns GC; Dage RC
    J Cardiovasc Pharmacol; 1994 Nov; 24(5):761-72. PubMed ID: 7532754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.